By

Luke Timmerman

2
Dec
2021

The Variant on the Move

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
22
Nov
2021

Reviving Targeted Radiopharmaceuticals for Cancer: Ken Song on The Long Run

Today’s guest on The Long Run is Ken Song. Ken is the CEO of San Diego-based RayzeBio. At RayzeBio, Ken discovered new opportunity in an area cancer R&D that had been long ago abandoned. It’s about creating targeted cancer therapies loaded with radioactive isotopes to give them extra tumor-killing punch. These aren’t the same thing as antibody-drug conjugates, in which...
Read More
16
Nov
2021

A Trek in the Himalayas for Cancer Research

The biotech community can do extraordinary things when fixated on a goal. Like curing cancer. I’m excited to announce today that I’m taking a team of biotech leaders on a mission to raise $1 million for cancer research at Fred Hutch. This group will come together on a trek to Everest Base Camp. It’s a legendary hike in the Himalayas...
Read More
8
Nov
2021

A Remarkable Life in Science: David Baltimore on The Long Run

Today’s guest on The Long Run is David Baltimore. David is one of the most accomplished biomedical scientists – and scientific citizens — of the past 50 years. He recently won Lasker~Koshland Award for Special Achievement. The award was granted “for the breadth and beauty of his discoveries in virology, immunology, and cancer; for his academic leadership; for his mentorship...
Read More
1 2 3 34